.jpg)
Dr. Jakob Magolan
Associate Professor, Dept. of Biochemistry and Biomedical Science
Boris Family Chair of Drug Discovery
Associate Member, Dept. of Chemistry and Chemical Biology
Member, Michael G. DeGroote Institute for Infectious Disease Research
Email:
Tel: 905-525-9140 ext. 22268
Office: Room 2234, MDCL (Michael Degroote Center for Learning and Discovery)
Mail: 1200 Main Street West, MDCL 2306
Hamilton, ON, L8N 3Z5, Canada
About Dr. Magolan
Dr. Magolan was born in Wloclawek, Poland and raised in Kitchener, Canada. He completed his undergraduate studies at Queen's University in Kingston, Canada, earning degrees in Chemistry and in Physical and Health Education, while playing some volleyball. As an undergraduate student, he worked with Prof. Robert Lemieux on the synthesis of new liquid crystals. He obtained his PhD in 2007 from Western University, London, Canada, under the mentorship of Prof. Michael Kerr, working on natural products synthesis and synthetic methodology. He then worked as postdoctoral researcher at the Griffith Institute for Drug Discovery in Brisbane, Australia in the field of anti-pancreatic cancer medicinal chemistry under guidance of Prof. Mark Coster. Dr. Magolan began his independent career in 2010 in the Department of Chemistry at University of Idaho where he established an NSF-funded research program in synthetic methodology and was the department's primary instructor of organic chemistry. He earned Tenure and Promotion to Associate Professor at the University of Idaho. He received recognition for his commitment to undergraduate research and education. In 2017, Dr. Magolan gave a TEDx talk about organic chemistry for a general audience that turned out to be much larger than his typical classes. Also in 2017, he moved his research program from Idaho to McMaster University where he is an Associate Professor in Department of Biochemistry and Biomedical Sciences and the inaugural holder of the Boris Family Endowed Chair of Drug Discovery. At McMaster, Dr. Magolan maintains an interest in new methods that enable efficient organic synthesis but his program is now primarily focused on interdiciplinary collaborative research under the broad theme of drug discovery in a range of therapeutic areas.